EE04188B1 - Crystallization method of the tetrahydropyridine derivative and formation of crystalline forms - Google Patents

Crystallization method of the tetrahydropyridine derivative and formation of crystalline forms

Info

Publication number
EE04188B1
EE04188B1 EEP199900264A EE9900264A EE04188B1 EE 04188 B1 EE04188 B1 EE 04188B1 EE P199900264 A EEP199900264 A EE P199900264A EE 9900264 A EE9900264 A EE 9900264A EE 04188 B1 EE04188 B1 EE 04188B1
Authority
EE
Estonia
Prior art keywords
formation
crystalline forms
crystallization method
tetrahydropyridine derivative
tetrahydropyridine
Prior art date
Application number
EEP199900264A
Other languages
Estonian (et)
Other versions
EE9900264A (en
Inventor
Caron Antoine
Franc Bruno
Monnier Olivier
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of EE9900264A publication Critical patent/EE9900264A/en
Publication of EE04188B1 publication Critical patent/EE04188B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP199900264A 1996-12-23 1997-12-23 Crystallization method of the tetrahydropyridine derivative and formation of crystalline forms EE04188B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (en) 1996-12-23 1996-12-23 PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED
PCT/FR1997/002393 WO1998028271A1 (en) 1996-12-23 1997-12-23 Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms

Publications (2)

Publication Number Publication Date
EE9900264A EE9900264A (en) 2000-02-15
EE04188B1 true EE04188B1 (en) 2003-12-15

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900264A EE04188B1 (en) 1996-12-23 1997-12-23 Crystallization method of the tetrahydropyridine derivative and formation of crystalline forms

Country Status (39)

Country Link
EP (1) EP0950050B1 (en)
JP (2) JP4499188B2 (en)
KR (1) KR100586670B1 (en)
CN (1) CN1129580C (en)
AR (1) AR009672A1 (en)
AT (1) ATE307802T1 (en)
AU (1) AU736697B2 (en)
BR (1) BR9714081A (en)
CA (1) CA2275596C (en)
CO (1) CO5070688A1 (en)
CZ (1) CZ296689B6 (en)
DE (1) DE69734460T2 (en)
DK (1) DK0950050T3 (en)
DZ (1) DZ2383A1 (en)
EE (1) EE04188B1 (en)
EG (1) EG21567A (en)
ES (1) ES2251038T3 (en)
FR (1) FR2757543B1 (en)
HK (1) HK1024002A1 (en)
HR (1) HRP970699B1 (en)
HU (1) HU227425B1 (en)
IL (1) IL129938A (en)
IN (1) IN186976B (en)
IS (1) IS2357B (en)
MY (1) MY118015A (en)
NO (1) NO312364B1 (en)
NZ (1) NZ336130A (en)
PL (1) PL190494B1 (en)
RS (1) RS49882B (en)
RU (1) RU2192416C2 (en)
SA (1) SA98180971B1 (en)
SI (1) SI0950050T1 (en)
SK (1) SK285088B6 (en)
TR (1) TR199901363T2 (en)
TW (1) TW518322B (en)
UA (1) UA60324C2 (en)
UY (1) UY24825A1 (en)
WO (1) WO1998028271A1 (en)
ZA (1) ZA9711576B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (en) * 1996-12-23 1999-04-02 Sanofi Sa PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED
FR2782082B3 (en) * 1998-08-05 2000-09-22 Sanofi Sa CRYSTALLINE FORMS OF (R) - (+) - N - [[3- [1-BENZOYL-3- (3,4- DICHLOROPHENYL) PIPERIDIN-3-YL] PROP-1-YL] -4-PHENYLPIPERIDIN-4 - YL] -N-METHYLACETAMIDE (OSANETANT) AND PROCESS FOR THE PREPARATION OF SAID COMPOUND
US9272068B2 (en) 2010-03-12 2016-03-01 Nippon Shokubai Co., Ltd. Process for producing water-absorbing resin
AP2013006779A0 (en) * 2011-04-15 2013-03-31 Emcure Pharmaceuticals Ltd An improved rilpivirine process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (en) * 1982-08-16 1984-02-17 Midy Spa SUBSTITUTED TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES WITH ANOREXIGENIC ACTIVITY, A PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS
FR2757543B1 (en) * 1996-12-23 1999-04-02 Sanofi Sa PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED

Also Published As

Publication number Publication date
CZ296689B6 (en) 2006-05-17
EE9900264A (en) 2000-02-15
CO5070688A1 (en) 2001-08-28
AU5668498A (en) 1998-07-17
DE69734460T2 (en) 2006-07-06
RS49882B (en) 2008-08-07
HRP970699B1 (en) 2007-03-31
YU28999A (en) 2003-01-31
FR2757543B1 (en) 1999-04-02
IS2357B (en) 2008-04-15
JP2001507012A (en) 2001-05-29
TW518322B (en) 2003-01-21
IS5076A (en) 1999-06-10
DK0950050T3 (en) 2006-01-23
PL190494B1 (en) 2005-12-30
CN1241180A (en) 2000-01-12
NO993076D0 (en) 1999-06-22
KR20000069504A (en) 2000-11-25
TR199901363T2 (en) 1999-08-23
NZ336130A (en) 2001-01-26
SK82899A3 (en) 1999-12-10
SI0950050T1 (en) 2006-04-30
FR2757543A1 (en) 1998-06-26
UA60324C2 (en) 2003-10-15
EG21567A (en) 2001-12-31
AR009672A1 (en) 2000-04-26
BR9714081A (en) 2000-05-09
DE69734460D1 (en) 2005-12-01
HUP0001387A3 (en) 2002-03-28
CN1129580C (en) 2003-12-03
CZ229299A3 (en) 1999-09-15
ZA9711576B (en) 1998-06-25
HRP970699A2 (en) 1998-10-31
SK285088B6 (en) 2006-06-01
AU736697B2 (en) 2001-08-02
NO993076L (en) 1999-06-22
SA98180971B1 (en) 2006-09-13
HU227425B1 (en) 2011-05-30
EP0950050B1 (en) 2005-10-26
MY118015A (en) 2004-08-30
IL129938A0 (en) 2000-02-29
CA2275596A1 (en) 1998-07-02
PL334256A1 (en) 2000-02-14
JP4499188B2 (en) 2010-07-07
KR100586670B1 (en) 2006-06-07
IN186976B (en) 2001-12-22
IL129938A (en) 2004-06-20
NO312364B1 (en) 2002-04-29
EP0950050A1 (en) 1999-10-20
DZ2383A1 (en) 2002-12-28
WO1998028271A1 (en) 1998-07-02
CA2275596C (en) 2005-10-11
RU2192416C2 (en) 2002-11-10
HUP0001387A2 (en) 2000-09-28
ES2251038T3 (en) 2006-04-16
HK1024002A1 (en) 2000-09-29
ATE307802T1 (en) 2005-11-15
UY24825A1 (en) 1998-04-21
JP2009197022A (en) 2009-09-03

Similar Documents

Publication Publication Date Title
EE9400366A (en) Crystalline metal alpha-2-interferons and method for their preparation and crystalline alpha-2-interferons
FI973750A0 (en) Preparation and crystalline forms of 2-methylthienobenzodiazepine
BR9711151A (en) Crystalline form of 4-¬5-methyl-3-phenylsoxazol-4-yl¾benzenesulfonamide
ATE238310T1 (en) CRYSTALLINE SUBSTANCE OF PIVOXIL CEFDITORS AND METHOD FOR THE PRODUCTION THEREOF
NO20011083L (en) Crystalline forms of EtOC2 - CH2 - (R) Cgl-Aze-Pab-OH
NO305025B1 (en) Process for the preparation of piperidine derivatives
FI962464A0 (en) Crystalline N-acetylamino acid derivatives and methods for their preparation
KR100287082B1 (en) Stereospecific Hydrolysis Method of Piperidinedione Derivatives
NO990792L (en) Method for inhibiting the expression of FAS
EE04188B1 (en) Crystallization method of the tetrahydropyridine derivative and formation of crystalline forms
NO20010553L (en) Crystalline forms of osanetant
NO308471B1 (en) Processes for the preparation of loracarbef monohydrate and crystalline anhydrate form of loracarbef
NO952668L (en) Method of Preparation of N-alkyl Lactams
IS5077A (en) Microfinite form of tetrahydropyridine derivative
NO20004583D0 (en) Crystalline form of paroxetine
UA26019C2 (en) METHOD OF PREPARATION OF THE CRYSTAL FOR TURNING
BR9610201A (en) Alternative crystalline form of tazofelone
SE9301393D0 (en) PROCEDURE FOR MANUFACTURE OF THE WOODWORK WITH RECTANGULAR SECTION

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20111223